Domain Partners I

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.

Axial Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. The company leverages its microbiome discovery platform to explore the gut-brain axis, which presents opportunities for creating innovative therapies aimed at enhancing the quality of life for individuals affected by neurological conditions. Founded in 2013 and based in Waltham, Massachusetts, Axial Therapeutics aims to address significant unmet medical needs within the CNS therapeutic landscape.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.

Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.

Nobias Therapeutics is a developer of rare pediatric disease drugs intended to cure rare illnesses in children. It focuses on discovering the genetic basis for rare diseases and develops drugs that can intervene in the affected pathways, enabling parents to help their infants become healthier.

Exalys Therapeutics is developing a portfolio of novel anti-inflammatory therapeutics with best-in-class properties to target a range of diseases with urgent unmet needs and limited treatment options. Exalys is initially targeting postoperative delirium, the most common complication of surgery in older patients and a key driver of poor health outcomes.

Seraphina Therapeutics, Inc. is a health and wellness company based in San Diego, California, focused on developing therapeutic solutions to address the comorbidities of aging and promote longevity. Founded in 2017, the company specializes in creating fatty acid supplements, micronutrients, food fortifiers, and nutritional interventions. These products aim to support cellular health, enhance mitochondrial function, and improve overall well-being, thereby helping individuals counter age-related decline. By advancing the understanding of micronutrient therapeutics, Seraphina Therapeutics seeks to improve mood, facilitate fat metabolism, and promote healthier aging.

Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing induced pluripotent stem cell therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company aims to create patient-specific restorative cell therapies that can alter the progression of the disease. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By integrating innovative genomic approaches with stem cell biology, Aspen Neuroscience seeks to advance the field of personalized medicine and improve treatment outcomes for patients suffering from Parkinson's disease.

Omniome, Inc. is a biotechnology company based in San Diego, California, established in 2013. It specializes in developing a proprietary DNA sequencing platform that aims to deliver high accuracy in sequencing results. The company employs its Sequencing By Binding technology, which enhances nucleotide and DNA matching by utilizing the natural matching capabilities of polymerase. This innovative approach not only provides precise and rapid results but also offers a cost-effective solution, which has the potential to significantly advance cancer diagnostics. Omniome is backed by prominent life sciences venture investors and is focused on becoming a trusted leader in the field of clinical sequencing.

ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, that specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using proprietary technology derived from Caltech. The company enhances the performance of quantitative polymerase chain reaction (qPCR) instruments, achieving a five-fold increase in multiplexing capabilities while maintaining cost-effectiveness. ChromaCode employs advanced bioinformatics techniques and patented mathematical methods to improve signal processing, enabling laboratories to conduct comprehensive testing of multiple targets in a single sample. Additionally, the company offers products such as the HDPCR Tick-Borne Pathogen Panel, which detects various tick-borne pathogens through a multiplex polymerase chain reaction test. Founded in 2012, ChromaCode draws expertise from professionals with backgrounds in leading organizations such as Illumina and Google[x].

Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing induced pluripotent stem cell therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company aims to create patient-specific restorative cell therapies that can alter the progression of the disease. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By integrating innovative genomic approaches with stem cell biology, Aspen Neuroscience seeks to advance the field of personalized medicine and improve treatment outcomes for patients suffering from Parkinson's disease.

Truvian Sciences Inc is a healthcare company that develops automated diagnostic equipment aimed at providing convenient and affordable health testing services. Based in San Diego, California, and incorporated in 2015, Truvian's technology integrates blood tests, immunoassays, and hematology assays into a single instrument, allowing for lab-accurate results in a shorter timeframe. This innovative approach enables healthcare professionals to access comprehensive and easy-to-understand lab test reports and insights. Additionally, Truvian's software platform facilitates communication between practitioners and patients, enhancing the overall experience of routine health testing.

Axial Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. The company leverages its microbiome discovery platform to explore the gut-brain axis, which presents opportunities for creating innovative therapies aimed at enhancing the quality of life for individuals affected by neurological conditions. Founded in 2013 and based in Waltham, Massachusetts, Axial Therapeutics aims to address significant unmet medical needs within the CNS therapeutic landscape.

Singular Genomics is a biotechnology company based in La Jolla, California, founded in 2016. It specializes in developing advanced gene sequencing technologies utilizing fluorescing molecular tags and novel next-generation sequencing and multiomics approaches. The company aims to empower researchers and clinicians through its innovative products, which include the G4 Sequencing Platform for next-generation sequencing and the PX Integrated Solution for single-cell analysis, spatial analysis, and proteomics. Singular Genomics is strategically located within a prominent biotech hub, adjacent to esteemed institutions such as the Salk Institute and UC San Diego, fostering collaboration and innovation in the rapidly growing genomics field. Its product offerings cater to a wide range of applications, including basic biology, oncology, and immunology, positioning the company as a key player in the life sciences sector.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on the development and commercialization of etripamil, a novel calcium channel blocker targeting various cardiovascular conditions. Etripamil is designed as a rapid-onset nasal spray for the self-administration by patients, specifically to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently advancing etripamil through Phase III clinical trials for PSVT in the United States and Canada, as well as conducting Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003, Milestone aims to address unmet medical needs in the treatment of transient cardiovascular conditions, including atrial fibrillation and angina.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Omniome, Inc. is a biotechnology company based in San Diego, California, established in 2013. It specializes in developing a proprietary DNA sequencing platform that aims to deliver high accuracy in sequencing results. The company employs its Sequencing By Binding technology, which enhances nucleotide and DNA matching by utilizing the natural matching capabilities of polymerase. This innovative approach not only provides precise and rapid results but also offers a cost-effective solution, which has the potential to significantly advance cancer diagnostics. Omniome is backed by prominent life sciences venture investors and is focused on becoming a trusted leader in the field of clinical sequencing.

WindMIL Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies for cancer patients, utilizing insights from bone marrow immunology. Established in 2015 and based in Princeton, New Jersey, the company specializes in a novel class of therapies known as Marrow Infiltrating Lymphocytes (MILs). These therapies are derived from memory T cells found in the bone marrow and involve reactivating dormant T-cells to create effective immunotherapies. By harnessing the unique immunologic properties of bone marrow, WindMIL Therapeutics aims to provide life-saving treatment options for individuals battling cancer.

Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.

Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on the development and commercialization of etripamil, a novel calcium channel blocker targeting various cardiovascular conditions. Etripamil is designed as a rapid-onset nasal spray for the self-administration by patients, specifically to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently advancing etripamil through Phase III clinical trials for PSVT in the United States and Canada, as well as conducting Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003, Milestone aims to address unmet medical needs in the treatment of transient cardiovascular conditions, including atrial fibrillation and angina.

Sebacia, Inc. is a medical device company based in Duluth, Georgia, specializing in light-based therapies for dermatological conditions, particularly acne. The company aims to provide innovative alternatives to traditional topical and systemic medications by utilizing a patented technology involving gold microparticles. These microparticles are applied to the skin and activated using a standard dermatology laser, selectively targeting the structures involved in acne. Developed in collaboration with researchers from Rice University and the Wellman Center of Photomedicine at Massachusetts General Hospital, Sebacia's approach addresses unmet needs in dermatology while offering a more effective treatment option for those affected by acne. Established in 2008, Sebacia continues to advance its technology with the goal of improving patient outcomes.

Iterum Therapeutics plc is a clinical-stage pharmaceutical company based in Dublin, Ireland, focused on developing innovative anti-infectives to address the global challenge of multi-drug resistant pathogens. Founded in 2015, the company is advancing sulopenem, a novel penem anti-infective compound available in both oral and intravenous formulations. Currently in Phase III clinical trials, sulopenem aims to treat uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. The company's goal is to provide effective solutions for serious infections caused by resistant bacteria, thereby improving patient outcomes and addressing the limitations of existing antibiotic treatments.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, that specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using proprietary technology derived from Caltech. The company enhances the performance of quantitative polymerase chain reaction (qPCR) instruments, achieving a five-fold increase in multiplexing capabilities while maintaining cost-effectiveness. ChromaCode employs advanced bioinformatics techniques and patented mathematical methods to improve signal processing, enabling laboratories to conduct comprehensive testing of multiple targets in a single sample. Additionally, the company offers products such as the HDPCR Tick-Borne Pathogen Panel, which detects various tick-borne pathogens through a multiplex polymerase chain reaction test. Founded in 2012, ChromaCode draws expertise from professionals with backgrounds in leading organizations such as Illumina and Google[x].

Dicerna Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovative treatments primarily for liver-related diseases, including rare inherited conditions, chronic liver diseases, and viral infections. Utilizing its proprietary GalXC RNA interference technology, Dicerna focuses on silencing disease-causing genes to address various health issues. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and belcesiran for genetic liver disease, among others. The company's extensive research efforts also encompass treatments for cardiovascular diseases and neurodegeneration. Dicerna has established strategic collaborations with prominent pharmaceutical companies to enhance its development capabilities. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna is at the forefront of advancing RNA-based therapeutics.

Adynxx a biopharmaceutical company, develops pain management drugs. It offers AYX1, a drug candidate to prevent acute post-operative pain and its transition into chronic pain; and AYX therapeutic programs, including long-term relief treatments for mature chronic pain syndromes. The company was incorporated in 2007 and is based in San Francisco, California.

Axial Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. The company leverages its microbiome discovery platform to explore the gut-brain axis, which presents opportunities for creating innovative therapies aimed at enhancing the quality of life for individuals affected by neurological conditions. Founded in 2013 and based in Waltham, Massachusetts, Axial Therapeutics aims to address significant unmet medical needs within the CNS therapeutic landscape.

Axial Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. The company leverages its microbiome discovery platform to explore the gut-brain axis, which presents opportunities for creating innovative therapies aimed at enhancing the quality of life for individuals affected by neurological conditions. Founded in 2013 and based in Waltham, Massachusetts, Axial Therapeutics aims to address significant unmet medical needs within the CNS therapeutic landscape.

ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.

Gene Sciences, Inc. is a biotechnology company based in San Diego, California, established in 2016. The company focuses on developing innovative DNA-targeted therapeutics aimed at modulating gene expression for the treatment of various human diseases. Serving customers primarily in the United States, Gene Sciences is dedicated to advancing healthcare solutions through its research and development efforts in the biopharmaceutical sector.

ROX Medical, Inc. is a medical device company based in San Clemente, California, specializing in interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). The company develops the ROX Coupler, which is designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, the device aims to improve oxygen delivery to tissues in COPD patients, helping to alleviate symptoms and enhance exercise tolerance. Founded in 2003, ROX Medical focuses on innovative solutions that enhance patient well-being through advanced medical technology.

BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.

Miramar Labs, founded in 2006 and based in Sunnyvale, California, specializes in developing medical devices for aesthetic applications. The company's primary product, the miraDry System, offers a non-invasive solution for adults suffering from primary axillary hyperhidrosis, which is excessive sweating in the underarm area. This innovative system employs microwave energy to selectively target and permanently eliminate sweat and odor glands, providing a long-lasting, non-surgical treatment option that enhances the confidence and quality of life for its users. The miraDry System is specifically designed for underarm treatment and is not applicable for hyperhidrosis in other areas of the body, such as the hands and feet.

Obalon Therapeutics, Inc. is a medical device company headquartered in Carlsbad, California, specializing in the development and commercialization of innovative devices for obesity treatment. The company is known for its Obalon Balloon System, which features a swallowable capsule containing an inflatable balloon that aids in weight loss for individuals with obesity. This system includes the Obalon Navigation System, a console that uses hardware and software to track the balloon's placement, and the Obalon Touch Inflation Dispenser, a semi-automated device for inflating the balloon after placement. Additionally, it provides a disposable canister filled with gas for inflation. Founded in 2008, Obalon has established itself as a leader in gastric balloon technology, emphasizing collaboration with clinicians to enhance treatment outcomes while prioritizing safety and performance. As of early 2020, the company operated three retail treatment centers in California.

BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.

Benvenue Medical, Inc. specializes in the design, manufacturing, and marketing of minimally invasive expandable implant systems for treating spinal disorders, specifically vertebral compression fractures and degenerative disc diseases. The company offers products such as the Kiva system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, aimed at treating various types of pathological vertebral compression fractures. Additionally, Benvenue Medical has introduced the Luna 3D, an expandable interbody fusion system designed for use in minimally invasive, mini-open, or open surgical procedures. Established in 2004 and headquartered in Santa Clara, California, the company serves a diverse customer base in the United States, Canada, Belgium, France, and Germany.

Singular Genomics is a biotechnology company based in La Jolla, California, founded in 2016. It specializes in developing advanced gene sequencing technologies utilizing fluorescing molecular tags and novel next-generation sequencing and multiomics approaches. The company aims to empower researchers and clinicians through its innovative products, which include the G4 Sequencing Platform for next-generation sequencing and the PX Integrated Solution for single-cell analysis, spatial analysis, and proteomics. Singular Genomics is strategically located within a prominent biotech hub, adjacent to esteemed institutions such as the Salk Institute and UC San Diego, fostering collaboration and innovation in the rapidly growing genomics field. Its product offerings cater to a wide range of applications, including basic biology, oncology, and immunology, positioning the company as a key player in the life sciences sector.

Singular Genomics is a biotechnology company based in La Jolla, California, founded in 2016. It specializes in developing advanced gene sequencing technologies utilizing fluorescing molecular tags and novel next-generation sequencing and multiomics approaches. The company aims to empower researchers and clinicians through its innovative products, which include the G4 Sequencing Platform for next-generation sequencing and the PX Integrated Solution for single-cell analysis, spatial analysis, and proteomics. Singular Genomics is strategically located within a prominent biotech hub, adjacent to esteemed institutions such as the Salk Institute and UC San Diego, fostering collaboration and innovation in the rapidly growing genomics field. Its product offerings cater to a wide range of applications, including basic biology, oncology, and immunology, positioning the company as a key player in the life sciences sector.

Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.

Kona Medical, Inc. is a medical technology company based in Issaquah, Washington, founded in 2009 by Dr. Michael Gertner. The company specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Its primary product, Surround Sound, is a hypertension therapy system that employs ultrasound imaging to precisely deliver focused ultrasound energy for renal denervation. This innovative approach targets the nerves associated with kidney function, offering a less invasive alternative for patients suffering from drug-resistant hypertension. By leveraging advancements in therapeutic focused ultrasound, Kona Medical seeks to improve treatment efficacy and reduce the health risks associated with high blood pressure.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of innovative cancer therapies. Its lead product candidate, entinostat, is a class I HDAC inhibitor currently undergoing Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, the company is developing SNDX-5613, an inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for specific types of acute leukemia. Syndax's pipeline also includes SNDX-6352, a monoclonal antibody designed to block the CSF-1 receptor, which is being tested for chronic graft versus host disease and various solid tumors. The company is pursuing multiple clinical collaborations and agreements with notable organizations, including MSD International and the National Cancer Institute, to enhance its research and development efforts. Founded in 2005, Syndax is dedicated to advancing treatment options for patients with solid tumors and hematological cancers.

Xagenic Inc. is a Toronto-based molecular diagnostics company focused on developing innovative technology for decentralized and rapid diagnostic testing. The company aims to enhance patient care by enabling on-demand, near-patient molecular testing, which allows clinicians to make informed treatment decisions during the initial consultation. Xagenic's technology facilitates rapid, enzyme-free detection of nucleic acids from clinical samples, yielding results in just 20 minutes. By commercializing a simple and fully automated platform, Xagenic is positioned to revolutionize diagnostic testing by enabling it to be conducted outside of traditional clinical laboratories. The company is also working on tests for infectious diseases that provide clinically actionable results in a timely manner, thereby improving overall healthcare efficiency and reducing costs.

Sebacia, Inc. is a medical device company based in Duluth, Georgia, specializing in light-based therapies for dermatological conditions, particularly acne. The company aims to provide innovative alternatives to traditional topical and systemic medications by utilizing a patented technology involving gold microparticles. These microparticles are applied to the skin and activated using a standard dermatology laser, selectively targeting the structures involved in acne. Developed in collaboration with researchers from Rice University and the Wellman Center of Photomedicine at Massachusetts General Hospital, Sebacia's approach addresses unmet needs in dermatology while offering a more effective treatment option for those affected by acne. Established in 2008, Sebacia continues to advance its technology with the goal of improving patient outcomes.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on the development and commercialization of etripamil, a novel calcium channel blocker targeting various cardiovascular conditions. Etripamil is designed as a rapid-onset nasal spray for the self-administration by patients, specifically to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently advancing etripamil through Phase III clinical trials for PSVT in the United States and Canada, as well as conducting Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003, Milestone aims to address unmet medical needs in the treatment of transient cardiovascular conditions, including atrial fibrillation and angina.

Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.

Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.

aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Obalon Therapeutics, Inc. is a medical device company headquartered in Carlsbad, California, specializing in the development and commercialization of innovative devices for obesity treatment. The company is known for its Obalon Balloon System, which features a swallowable capsule containing an inflatable balloon that aids in weight loss for individuals with obesity. This system includes the Obalon Navigation System, a console that uses hardware and software to track the balloon's placement, and the Obalon Touch Inflation Dispenser, a semi-automated device for inflating the balloon after placement. Additionally, it provides a disposable canister filled with gas for inflation. Founded in 2008, Obalon has established itself as a leader in gastric balloon technology, emphasizing collaboration with clinicians to enhance treatment outcomes while prioritizing safety and performance. As of early 2020, the company operated three retail treatment centers in California.

CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, founded in 2008. The company specializes in developing diagnostic tests aimed at predicting a woman's individualized risk of premature birth, preeclampsia, and other pregnancy-related complications. By utilizing proprietary biomarkers, Sera Prognostics seeks to address the significant economic and healthcare challenges associated with premature births, impacting infants, families, and society at large. The company has licensed advanced serum proteomics technology and innovative peptides from Brigham Young University and the University of Utah to support its research and development efforts.

BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, founded in 2008. The company specializes in developing diagnostic tests aimed at predicting a woman's individualized risk of premature birth, preeclampsia, and other pregnancy-related complications. By utilizing proprietary biomarkers, Sera Prognostics seeks to address the significant economic and healthcare challenges associated with premature births, impacting infants, families, and society at large. The company has licensed advanced serum proteomics technology and innovative peptides from Brigham Young University and the University of Utah to support its research and development efforts.

Miramar Labs, founded in 2006 and based in Sunnyvale, California, specializes in developing medical devices for aesthetic applications. The company's primary product, the miraDry System, offers a non-invasive solution for adults suffering from primary axillary hyperhidrosis, which is excessive sweating in the underarm area. This innovative system employs microwave energy to selectively target and permanently eliminate sweat and odor glands, providing a long-lasting, non-surgical treatment option that enhances the confidence and quality of life for its users. The miraDry System is specifically designed for underarm treatment and is not applicable for hyperhidrosis in other areas of the body, such as the hands and feet.

Zyga Technology, Inc. is a medical device company focused on the research, design, development, and commercialization of minimally invasive solutions for lumbar spine conditions. The company offers the SImmetry Sacroiliac Joint Fusion System, which addresses various issues such as sacroiliac joint disruptions and degenerative sacroiliitis. Additionally, Zyga is developing the Glyder Facet Restoration System, an investigational device aimed at treating chronic facetogenic pain. Founded in 2008 and based in Minnetonka, Minnesota, Zyga Technology combines a skilled team of engineers, marketing professionals, and management with extensive experience in the spine industry. As of December 31, 2017, Zyga operates as a subsidiary of RTI Surgical, Inc.

VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops and commercializes Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory, and inflammatory diseases. It provides Motolimod, a lead investigational drug to mobilize a patient's own immune system by directly activating myeloid dendritic cells, monocytes, and natural killer cells to fight cancer. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is based in Seattle, Washington. As of February 28, 2017, VentiRx Pharmaceuticals, Inc. operates as a subsidiary of Celgene Corporation.

Colorescience, Inc. specializes in the production and sale of mineral-based cosmetics and sunscreen products. Founded in 2000 and based in Carlsbad, California, the company offers a range of treatment products aimed at addressing various skin concerns, including pigmentation, redness, dark circles, and signs of aging, as well as catering to different skin types such as sensitive, oily, and dry skin. Its product line includes UV protectors, primers, foundations, and enhancers, all designed with high-quality ingredients and formulations. Colorescience distinguishes itself in the luxury aesthetic makeup market by focusing on efficacy and ease of use. The company distributes its products through a network of licensed physicians, luxury spas, retailers, and online channels, emphasizing its commitment to reducing skin cancer and other skin conditions.

Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Xagenic Inc. is a Toronto-based molecular diagnostics company focused on developing innovative technology for decentralized and rapid diagnostic testing. The company aims to enhance patient care by enabling on-demand, near-patient molecular testing, which allows clinicians to make informed treatment decisions during the initial consultation. Xagenic's technology facilitates rapid, enzyme-free detection of nucleic acids from clinical samples, yielding results in just 20 minutes. By commercializing a simple and fully automated platform, Xagenic is positioned to revolutionize diagnostic testing by enabling it to be conducted outside of traditional clinical laboratories. The company is also working on tests for infectious diseases that provide clinically actionable results in a timely manner, thereby improving overall healthcare efficiency and reducing costs.

Benvenue Medical, Inc. specializes in the design, manufacturing, and marketing of minimally invasive expandable implant systems for treating spinal disorders, specifically vertebral compression fractures and degenerative disc diseases. The company offers products such as the Kiva system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, aimed at treating various types of pathological vertebral compression fractures. Additionally, Benvenue Medical has introduced the Luna 3D, an expandable interbody fusion system designed for use in minimally invasive, mini-open, or open surgical procedures. Established in 2004 and headquartered in Santa Clara, California, the company serves a diverse customer base in the United States, Canada, Belgium, France, and Germany.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing therapeutics for ear-related diseases and disorders. The company offers OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-release formulation of dexamethasone currently in Phase III trials for Ménière's disease, and OTO-313, which targets tinnitus and is in Phase I/II trials. Additionally, OTO-413 aims to treat cochlear synaptopathy and related hearing difficulties, while OTO-510 seeks to prevent hearing loss from cisplatin treatment. Another candidate, OTO-6XX, focuses on hair cell regeneration for severe hearing loss. Founded in 2008, Otonomy collaborates with various institutions and companies to enhance its research and development efforts in localized drug delivery for otologic disorders.

Smart Medical Systems Ltd. develops, manufactures, and commercializes medical devices specializing in the field of gastroenterology and gastrointestinal (GI) endoscopy. The company offers NaviAid Platform designed to overcome the challenges in GI endoscopy; G-EYE endoscope that enables Controlled Withdrawal of the endoscope during colonoscopy, improving visibility of the colon and making therapy and intervention easier and faster; NaviAid AB (Advancing Balloon) device that provides ileoscopy/upper enteroscopy while using standard endoscopes; NaviAid ABC (Advancing Balloon for Colonoscopy) device for colonoscopy; NaviAid inflation systems that facilitate the operation of various balloon devices within the gastrointestinal tract; and Controlled Withdrawal technique, a feature of the G-EYE endoscope and the NaviAid family that enables a thorough investigation of the bowel, improving visibility, detection, and stability of the endoscope. It serves customers through distributors in the United States and Europe. The company is based in Ra’anana, Israel with a subsidiary operation in the United States.

Founded in 2007, Sequent Medical, Inc. is a privately-held venture backed medical device company dedicated to the development of innovative catheter-based neurovascular technologies. The company has invented and developed the proprietary Microbraid™ technology to create the WEB™ Aneurysm Embolization System, a compelling and versatile new option for the treatment of both ruptured and unruptured aneurysms. The WEB has received the CE mark and to date has been used to treat a wide variety of nearly 600 aneurysms in Europe, Latin America and New Zealand. The WEB is not available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California and has European operations based in Bonn, Germany.

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Atara Biotherapeutics is an off-the-shelf T-cell immunotherapy company based in South San Francisco, California, focused on developing innovative treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead product, tabelecleucel (tab-cel), is currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, with additional development for other EBV-related hematologic malignancies and solid tumors, such as nasopharyngeal carcinoma. Atara is also advancing next-generation CAR T immunotherapies, addressing various conditions including mesothelin-targeted therapies for solid tumors and treatments for B-cell lymphomas. Other notable candidates include therapies for multiple sclerosis and several viral infections. The company collaborates with esteemed institutions such as Memorial Sloan Kettering Cancer Center and Bayer AG to enhance its research and development efforts. Founded in 2012, Atara Biotherapeutics is committed to transforming the treatment landscape for serious diseases through its robust clinical and scientific initiatives.

Atara Biotherapeutics is an off-the-shelf T-cell immunotherapy company based in South San Francisco, California, focused on developing innovative treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead product, tabelecleucel (tab-cel), is currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, with additional development for other EBV-related hematologic malignancies and solid tumors, such as nasopharyngeal carcinoma. Atara is also advancing next-generation CAR T immunotherapies, addressing various conditions including mesothelin-targeted therapies for solid tumors and treatments for B-cell lymphomas. Other notable candidates include therapies for multiple sclerosis and several viral infections. The company collaborates with esteemed institutions such as Memorial Sloan Kettering Cancer Center and Bayer AG to enhance its research and development efforts. Founded in 2012, Atara Biotherapeutics is committed to transforming the treatment landscape for serious diseases through its robust clinical and scientific initiatives.

RightCare Solutions, founded in 2011 and based in Horsham, Pennsylvania, specializes in evidence-based technology aimed at enhancing hospital discharge planning and managing patient readmissions. The company's proprietary Discharge Decision Support System, known as D2S2, empowers healthcare providers—including hospitals, insurers, and homecare agencies—to optimize their discharge processes. By enabling the identification and prediction of high-risk patients at the time of admission, RightCare Solutions helps improve patient outcomes and the overall quality of care. This approach not only supports healthcare providers in reducing the burden of 30-day readmissions but also contributes to a more effective continuum of care.

Novadigm Therapeutics is an immunotherapeutic company focused on developing vaccines to protect patients from fungal and bacterial infections. Founded in 2005 and headquartered in Grand Forks, North Dakota, the company is advancing its product pipeline, which includes NDV-3, a vaccine showing preclinical efficacy in lessening the severity of infections caused by various pathogens. Additionally, Novadigm is working on Als3, an antigen vaccine that targets systemic and mucosal candidal infections. By utilizing a recombinant form of the Als3 surface protein, the company aims to enhance the immune response, allowing patients to better withstand potential infections.

BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing therapeutics for ear-related diseases and disorders. The company offers OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-release formulation of dexamethasone currently in Phase III trials for Ménière's disease, and OTO-313, which targets tinnitus and is in Phase I/II trials. Additionally, OTO-413 aims to treat cochlear synaptopathy and related hearing difficulties, while OTO-510 seeks to prevent hearing loss from cisplatin treatment. Another candidate, OTO-6XX, focuses on hair cell regeneration for severe hearing loss. Founded in 2008, Otonomy collaborates with various institutions and companies to enhance its research and development efforts in localized drug delivery for otologic disorders.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of innovative cancer therapies. Its lead product candidate, entinostat, is a class I HDAC inhibitor currently undergoing Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, the company is developing SNDX-5613, an inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for specific types of acute leukemia. Syndax's pipeline also includes SNDX-6352, a monoclonal antibody designed to block the CSF-1 receptor, which is being tested for chronic graft versus host disease and various solid tumors. The company is pursuing multiple clinical collaborations and agreements with notable organizations, including MSD International and the National Cancer Institute, to enhance its research and development efforts. Founded in 2005, Syndax is dedicated to advancing treatment options for patients with solid tumors and hematological cancers.

Applied Proteomics, Inc. specializes in developing noninvasive, blood-based tests for the early detection and monitoring of diseases, leveraging its advanced protein biomarker discovery platform. Founded in 2006 and headquartered in San Diego, California, the company focuses on the application of proteomics to enhance diagnostics, companion diagnostics, and personalized medicine. Its innovative platform integrates improved instrumentation, accelerated computing, and comprehensive genome annotations, supported by stringent quality controls and standard operating procedures. This robust approach enables the detection of diseases at their earliest stages by analyzing the body's proteome, thereby supporting better medical decisions and patient care. Among its offerings is the SimpliPro Colon test, which reflects the company's commitment to improving health diagnostics through protein-based molecular diagnostics.

Dicerna Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovative treatments primarily for liver-related diseases, including rare inherited conditions, chronic liver diseases, and viral infections. Utilizing its proprietary GalXC RNA interference technology, Dicerna focuses on silencing disease-causing genes to address various health issues. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and belcesiran for genetic liver disease, among others. The company's extensive research efforts also encompass treatments for cardiovascular diseases and neurodegeneration. Dicerna has established strategic collaborations with prominent pharmaceutical companies to enhance its development capabilities. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna is at the forefront of advancing RNA-based therapeutics.

ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.

aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Veracyte, Inc. is a genomic diagnostics company that specializes in developing tests for various cancers and other diseases, including thyroid and lung cancers. Its key products include the Afirma Genomic Sequencing Classifier, which helps identify benign thyroid nodules to avoid unnecessary surgeries, and the Percepta Genomic Sequencing Classifier for lung cancer patients. Additionally, Veracyte offers the Envisia Genomic Classifier for distinguishing idiopathic pulmonary fibrosis from other lung diseases, and the Prosigna Breast Cancer Prognostic Gene Signature Assay to assess the risk of cancer recurrence. The company markets its products through a team of specialists and has established collaborations with Johnson & Johnson Innovation and Loxo Oncology to enhance the development of innovative diagnostic tests. Founded in 2008 and based in South San Francisco, California, Veracyte was previously known as Calderome, Inc. and aims to improve clinical outcomes by refining diagnostic methods.

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Founded in 2008 and headquartered in Ann Arbor, Michigan, the company specializes in non-statin medications aimed at treating conditions such as atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia. Its primary product candidates include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are designed to improve cholesterol management. Esperion also explores novel treatment approaches, including HDL Therapy, based on its understanding of high-density lipoprotein function. The company collaborates with Daiichi Sankyo Europe GmbH to enhance its research and development efforts.

ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.

Afferent Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It develops medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. The company’s AF-219, a compound that completed two Phase 1 clinical studies. Afferent Pharmaceuticals, Inc. was founded in 2009 and is based in San Mateo, California.

Atara Biotherapeutics is an off-the-shelf T-cell immunotherapy company based in South San Francisco, California, focused on developing innovative treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead product, tabelecleucel (tab-cel), is currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, with additional development for other EBV-related hematologic malignancies and solid tumors, such as nasopharyngeal carcinoma. Atara is also advancing next-generation CAR T immunotherapies, addressing various conditions including mesothelin-targeted therapies for solid tumors and treatments for B-cell lymphomas. Other notable candidates include therapies for multiple sclerosis and several viral infections. The company collaborates with esteemed institutions such as Memorial Sloan Kettering Cancer Center and Bayer AG to enhance its research and development efforts. Founded in 2012, Atara Biotherapeutics is committed to transforming the treatment landscape for serious diseases through its robust clinical and scientific initiatives.

Achaogen, Inc. is a biopharmaceutical company focused on developing antibacterial agents to combat multi-drug resistant (MDR) gram-negative infections. The company's primary product, plazomicin, is designed to treat serious bacterial infections caused by MDR enterobacteriaceae, particularly carbapenem-resistant strains. Additionally, Achaogen is working on C-Scape, an orally-administered combination therapy targeting infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established several collaboration agreements, including partnerships with Thermo Fisher Scientific for assay development, and Ionis Pharmaceuticals for the advancement of aminoglycoside antibacterial compounds. The company generates revenue primarily through government contracts for research and development. Founded in 2002 and based in South San Francisco, California, Achaogen filed for Chapter 11 bankruptcy in April 2019, transitioning to a liquidation plan in May 2020.

Glaukos Corporation is an ophthalmic medical technology company dedicated to developing innovative products and procedures aimed at transforming the treatment of glaucoma, a leading cause of blindness globally. The company has pioneered Micro-Invasive Glaucoma Surgery (MIGS), fundamentally changing the approach to glaucoma management. Their flagship product, the iStent®, launched in the United States in 2012, is recognized as one of the smallest medical devices ever approved by the FDA, designed to reduce intraocular pressure in patients with mild-to-moderate open-angle glaucoma. In addition to the iStent, Glaukos is expanding its product pipeline with the iStent SA, a trabecular micro-bypass system designed for standalone procedures. Founded in 1998 and headquartered in San Clemente, California, Glaukos aims to address a wide range of glaucoma disease states with its comprehensive portfolio of injectable micro-scale therapies.

Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings. The company was founded in 2003 and is based in Branford, Connecticut.

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronary intervention. It was founded in 2001 and headquartered in Durham, North Carolina.

Kona Medical, Inc. is a medical technology company based in Issaquah, Washington, founded in 2009 by Dr. Michael Gertner. The company specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Its primary product, Surround Sound, is a hypertension therapy system that employs ultrasound imaging to precisely deliver focused ultrasound energy for renal denervation. This innovative approach targets the nerves associated with kidney function, offering a less invasive alternative for patients suffering from drug-resistant hypertension. By leveraging advancements in therapeutic focused ultrasound, Kona Medical seeks to improve treatment efficacy and reduce the health risks associated with high blood pressure.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

RightCare Solutions, founded in 2011 and based in Horsham, Pennsylvania, specializes in evidence-based technology aimed at enhancing hospital discharge planning and managing patient readmissions. The company's proprietary Discharge Decision Support System, known as D2S2, empowers healthcare providers—including hospitals, insurers, and homecare agencies—to optimize their discharge processes. By enabling the identification and prediction of high-risk patients at the time of admission, RightCare Solutions helps improve patient outcomes and the overall quality of care. This approach not only supports healthcare providers in reducing the burden of 30-day readmissions but also contributes to a more effective continuum of care.

Cotera, Inc. is engaged in the design and development of orthopedic implants aimed at treating knee osteoarthritis. The company's flagship product, the Latella device, is surgically attached to the femur and is intended to alleviate medial knee pain by shifting muscles and tendons to redirect the forces exerted on the joint. Founded in 2011 and headquartered in Menlo Park, California, Cotera focuses on innovative solutions in the field of orthopedic care, specifically targeting conditions that affect joint function and patient mobility.

Veracyte, Inc. is a genomic diagnostics company that specializes in developing tests for various cancers and other diseases, including thyroid and lung cancers. Its key products include the Afirma Genomic Sequencing Classifier, which helps identify benign thyroid nodules to avoid unnecessary surgeries, and the Percepta Genomic Sequencing Classifier for lung cancer patients. Additionally, Veracyte offers the Envisia Genomic Classifier for distinguishing idiopathic pulmonary fibrosis from other lung diseases, and the Prosigna Breast Cancer Prognostic Gene Signature Assay to assess the risk of cancer recurrence. The company markets its products through a team of specialists and has established collaborations with Johnson & Johnson Innovation and Loxo Oncology to enhance the development of innovative diagnostic tests. Founded in 2008 and based in South San Francisco, California, Veracyte was previously known as Calderome, Inc. and aims to improve clinical outcomes by refining diagnostic methods.

Tandem Diabetes Care, Inc. develops medical devices for the treatment of diabetes. It offers diabetic insulin pumps for adults and children to diabetes needs, including keeping blood glucose levels within target ranges. The company focuses on insulin infusion therapy. Tandem Diabetes Care, Inc. was incorporated in 2006 and is based in San Diego, California.

ROX Medical, Inc. is a medical device company based in San Clemente, California, specializing in interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). The company develops the ROX Coupler, which is designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, the device aims to improve oxygen delivery to tissues in COPD patients, helping to alleviate symptoms and enhance exercise tolerance. Founded in 2003, ROX Medical focuses on innovative solutions that enhance patient well-being through advanced medical technology.

Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.

Obalon Therapeutics, Inc. is a medical device company headquartered in Carlsbad, California, specializing in the development and commercialization of innovative devices for obesity treatment. The company is known for its Obalon Balloon System, which features a swallowable capsule containing an inflatable balloon that aids in weight loss for individuals with obesity. This system includes the Obalon Navigation System, a console that uses hardware and software to track the balloon's placement, and the Obalon Touch Inflation Dispenser, a semi-automated device for inflating the balloon after placement. Additionally, it provides a disposable canister filled with gas for inflation. Founded in 2008, Obalon has established itself as a leader in gastric balloon technology, emphasizing collaboration with clinicians to enhance treatment outcomes while prioritizing safety and performance. As of early 2020, the company operated three retail treatment centers in California.

BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.